يعرض 1 - 20 نتائج من 44 نتيجة بحث عن '"Domínguez, Martha C"', وقت الاستعلام: 0.48s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
  3. 3
    Academic Journal
  4. 4
    Academic Journal
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
    Academic Journal

    المصدر: Biomedica; Vol. 29 No. 2 (2009); 218-231 ; Biomédica; Vol. 29 Núm. 2 (2009); 218-231 ; 2590-7379 ; 0120-4157

    وصف الملف: application/pdf

    Relation: https://revistabiomedica.org/index.php/biomedica/article/view/24/25; https://revistabiomedica.org/index.php/biomedica/article/view/24/306; Poiesz BJ, Ruscetti FW, Gadzar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415-9. 2. Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med. 2000;18:109-19. 3. Quintana M, Villalobos J, Domínguez M, Tamayo O, García-Vallejo F. Estudio de la seroprevalencia de la infección por los virus linfotrópicos humanos (HTLV) I y II en poblaciones del departamento de Córdoba, Colombia. Colombia Médica. 2004;35:22-30. 4. García-Vallejo F. Caracterización molecular y genómica del proceso de integración del provirus del virus linfotropico humano (HTLV) tipo I. Rev Acad Colomb Cienc. 2006;30:155-70. 5. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA.1984;81:2534-7. 6. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475-96. 7. Leclerq I, Mortreux F, Gabet AS, Jonson CB, Wattel E. Basis of HTLV type I site selection. AIDS Res Hum Retroviruses. 2000;16:1653-9. 8. Zoubak S, Richardson J, Rynditch AV, Hollsberg P, Hafler DA, Boeri E, et al. Regional specificity of HTLV-I proviral integration in the human genome. Gene. 1994;143:155-63. 9. Glukhova LA, Zoubak SV, Rynditch AV, Miller GG, Titova IV, Vorovyeva N, et al. Localization of HTLV-1 and HIV-1 proviral sequences in chromosomes of persistently infected cells. Chromosome Res.1999;7:177-83. 10. Richarsond JH, Rose NJ, Mann S, Ferguson-Smith M, Lever AM. Chromosomal positioning of human T-lymphotropic type I proviruses by fluorescent in situ hybridisation. J Virol Methods. 2001;93 65-74. 11. Saccone S, De Sario A, Wiegant J, Raap AK, Della-Valle G, Bernardi G. Correlations between isochores and chromosomal bands in the human genome. Proc Natl Acad Sci USA. 1993;90:11929-33. 12. Woodfine K, Fiegler H, Beare DM, Collins JE, McCann OT, Young BD, et al. Replication timing of the human genome. Hum Mol Genet. 2004;13:191-202. 13. Saccone S, Cacciò S, Kusuda J, Andreozzi L, Bernardi G. Identification of the gene-richest bands in human chromosomes. Gene. 1996;174:85-94. 14. Kim MA, Johannsmann R, Grzeschik KH. Giemsa staining of the sites replicating DNA early in human lymphocyte chromosomes. Cytogenet Cell Genet. 1975;15:363-71. 15. Federico C, Saccone S, Bernardi G. The gene-richest bands of human chromosomes replicate at the onset of the S-phase. Cytogenet Cell Genet. 1998;80:83-8. 16. Albrecht B, Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev. 2002;66:396-406. 17. Yasunaga JI, Matsuoka M. Human T-cell leukemia virus type I induces adult T-cell leukemia: From clinical aspects to molecular mechanisms. Cancer Control. 2007;14:133-40. 18. Albrecht B, Collins ND, Burrinstom MT, Nisbet JW, Ratner L, Green PL, et al. Human T-lymphotropic virus type I open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol. 2000;74:9828-35. 19. Bindhu M, Nair A, Lairmore MD. Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci. 2004;9: 2556-76. 20. Carrascal E, Cortés A, Akiba S, Tamayo O, Quiñónez F, Floréz L, et al. Epidemiología y patología de la leucemia/linfoma de células T del adulto en Cali y el suroccidente colombiano. Colombia Médica. 2004;35:12-7. 21. República de Colombia. Ministerio de Salud. Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud Resolución No 008430 de octubre 4 de 1993. Bogotá: Ministerio de Salud; 1993. 22. Sambrook J, Fritzch EF, Maniatis T. Molecular cloning. A laboratory manual. New York: Ed. Cold Spring Harbor Press; 1989. 23. Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci USA. 1983;80:3618-22. 24. Feinberg AP, Vogelstein B. Technique for radiolabeling of restriction endonuclease fragments. Anal Biochem. 1983;132:6-13. 25. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, et al. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature.1981;294:770-1. 26. Takemoto S, Matsuoka M, Yamaguchi K, Takatsuki K. A novel diagnostic method of adult T-cell leukemia: Monoclonal integration of human T-cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction. Blood. 1994;84:3080-5. 27. Cavrois M, Gessain A, Wain-Hobson S, Wattel E. Proliferation of HTLV-I infected circulating cells in vivo in all asymptomatic carries and patients with TSP/HAM. Oncogen. 1996;12:2419-23. 28. Cabrera J, García-Vallejo F. Aumento del número de amplicones obtenidos por IPCR en el ADN de personas seropositivas para HTLV-I afectadas con PET/HAM. Colombia Médica. 2000;31:169-75. 29. Ozawa T, Itoyama T, Sadamori N, Yamada Y, Hata T, Tomonaga M, et al. Rapid isolation of viral integration site reveals frequent integration of HTLV-1 into expressed loci. J Hum Genet. 2004;49:154-29. 30. STATA CORP. Stata Statistical Software: Release 8.0. College Station TX: Stata Corporative; 2000. 31. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291:1304-51. 32. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921. 33. Blank A. Adult T-cell leukemia/lymphoma in southwest Colombia. En: HTLV, truths and questions. Cali: Edit Zaninovic; 1996. p. 266-71. 34. Wattel E, Vartanian JP, Pannetier CH, Wain-Hobson S. Clonal expansión of human T-cell leukemia and symptomatic carries without malignancy. J. Virol. 1995;69:2863-8. 35. Wattel E, Cavrois, Gessain MA, Wain-Hobson S. Clonal expansion of infected cells –a way of life for HTLV-I. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(Supl.1):92-9. 36. Doi K, Wu X, Taniguchi Y, Yasunaga J, Satou Y, Okayama A, et al. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier status. Blood. 2005;106:1048-53. 37. Hanai S, Nitta T, Shoda M, Tanaka M, Iso N, Mizoguchi I, et al. Integration of human T-cell leukemia virus type 1 in genes of leukemia cells of patients with adult T-cell leukemia. Cancer Sci. 2004;95:306-10. 38. Spence JM, Mills W, Mann K, Huxley C, Farr CJ. Increased missegregation and chromosome loss with decreasing chromosome size in vertebrate cells. Chromosoma. 2006;115:60-74. 39. Leclercq I, Mortreux F, Cavrois M, Leroy A, Gessain A, Wain-Hobson S, et al. Host sequences flanking the human T-cell leukemia virus type 1 provirus in vivo. J Virol. 2000;74:2305-12. 40. Oliver JL, Carpena P, Román-Rolatán R, Mata-Balaguer T, Mejias-Romero A, Hackenberg M, et al. Isochore chromosome maps of the human genome. Gene. 2002;300:117-27. 41. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998; 396:643-9. 42. Pavlícek A, Jabbari K, Paces J, Paces V, Hejnar J, Bernardi G. Similar integration but different stability of Alus and LINEs in the human genome. Gene. 2001;276:39-45. 43. Tsuji T, Sugahara K, Tsuruda K, Uemura A, Harasawa H, Hasegawa H, et al. Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells. Int J Hematol. 2004;80:254-60. 44. Derce D, Crise B, Li Y, Princler G, Lum N, Stewart C, et al. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol. 2007;81:6731-41. 45. Agbottah E, Deng L, Dannenberg LO, Pumfery A, Kashanchi F. Effect of SWI/SNF chromatin remodeling complex on HIV-1 Tat activated transcription. Retrovirology. 2006;3:48-67. 46. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004;2:1127-37. 47. Wu X, Burgess S M. Integration target site selection for retroviruses and transposable elements. Cell Mol Life Sci. 2004;61:2588-96. 48. Versteeg R, van Schaik BD, van Batenburg MF, Roos M, Monajemi R, Caron H, et al. The human transcriptome map reveals extremes in gene density, intron length, GC content, and repeat pattern for domains of highly and weakly wxpressed genes. Genome Res. 2003;13:1998-2004.; https://revistabiomedica.org/index.php/biomedica/article/view/24

  10. 10
    Electronic Resource
  11. 11
    Academic Journal

    المصدر: Biomedica; Vol. 28 No. 3 (2008); 448-459 ; Biomédica; Vol. 28 Núm. 3 (2008); 448-459 ; 2590-7379 ; 0120-4157

    وصف الملف: application/pdf

    Relation: https://revistabiomedica.org/index.php/biomedica/article/view/85/83; Neufeld E, Muenzer J. The mucopolysaccharidosis. En: Scriver C, Beaudet A, Sly W, Valle D, editores. The metabolic and molecular bases of inherited diseases. New York: McGraw-Hill; 2001. p. 3421-52. 2. Montaño AM, Tomatsu S, Gottesman G, Smith M, Orii T. International Morquio A registry: Clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165-74. 3. Tomatsu S, Montaño A, Nishioka T, Gutiérrez M, Peña O, Trandafirescu G, et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat. 2005;26:500-12. 4. Northover H, Cowie RA, Wraith JE. Mucopoly-saccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996;19:357-65. 5. Cheng SH, Smith AE. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther. 2003;10:1275-81. 6. Tomatsu S, Fukuda M, Masue K, Sukegawa T, Fukao A, Yamagishi T, et al. Morquio disease: isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase. Biochem Biophys Res Commun. 1991;181:677-83. 7. Cooper D, Ball E, Stenson P, Phillips A, Howells K, Mort M. The Human Gene Mutation Data Base at the Institute of Medical Genetics in Cardiff. Consultado: los autores deben colocar la fecha de consulta. Disponible en: http://www.hgmd.cf.ac.uk. 8. Kato Z, Fukuda S, Tomatsu S, Vega H, Yasunaga T, Yamahishi A, et al. A Novel Common Missense Mutation G301C in the N-Acetylgalactosamine-6-sulfate Sulfatase Gene in Mucopolysaccharidosis IVA. Hum Genet. 1997;101:97-101. 9. Bernal J, Briceño I. Genetic and other diseases in the pottery of Tumaco-La Tolita culture in Colombia-Ecuador. Clin Genet. 2006;70:188-91. 10. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A. 1997;94:5804-9. 11. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270-6. 12. Rutledge EA, Russell DW. Adeno-associated virus vector integration junctions. J Virol. 1997;71:8429-36. 13. Xiao W, Berta SC, Lu MM, Moscioni AD, Tazelaar J, Wilson JM. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol. 1998;72:10222-6. 14. Xiao X, Li J, Samulski R. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224-32. 15. Fisher KJ, Kelley WM, Burda JF, Wilson JM. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther. 1996;7:2079-87. 16. Vincent KA, Piraino ST, Wadsworth SC. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. J Virol. 1997;71:1897-905. 17. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 1989;63:3822-8. 18. Sands M, Davidson B. Gene therapy for lysosomal storage diseases. Mol Ther. 2006;13:839-49. 19. Daly TM, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci USA. 1999;96:2296-300. 20. McEachern K, Nietupski J, Chuang W, Armentano D, Johnson J, Hutto E, et al. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med. 2006;8:719-29. 21. Daly TM, Ohlemiller KK, Roberts MS, Vogler CA, Sands MS. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 2001;8:1291-8. 22. Fraites TJ Jr, Schleissing MR, Shanely RA, Walter GA, Cloutier DA, Zolotukhin I, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther. 2002;5:571-8. 23. Park J, Murray GJ, Limaye A, Quirk JM, Gelderman MP, Brady RO, et al. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci USA. 2003;100:3450-4. 24. Hennig AK, Ogilvie JM, Ohlemiller KK, Timmers AM, Hauswirth WW, Sands MS. AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol Ther. 2004;10:106-116. 25. Daly TM, Okuyama T, Vogler C, Haskins ME, Muzyczka N, Sands MS. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology inmucopolysa-ccharidosis type VII mice. Hum Gene Ther. 1999;10: 85-94. 26. Ponder K, Haskins M. Gene therapy for muco- polysaccharidosis. Expert Opin Biol Ther. 2007;7: 1333-45. 27. Miwa K, Matsui K, Terabe M, Ito K, Ishida M, Takagi H, et al. Construction of novel shuttle vectors and a cosmid vector for the glutamic acid-producing bacteria Brevibacterium lactofermentum and Corynebacterium glutamicum. Gene. 1985;39:281-6. 28. Grimm D, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinschmidtl J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 1999; 6: 1322-30. 29. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA. 1995;92:5719-23. 30. vanDiggelen O, Zhao H, Kleijer W, Janse H, Poorthuis B, Pelt JV, et al. A fluorometric enzyme assay for the diagnosis of Morquio type A. Clin Chem Acta. 1990;187:131-40. 31. Barrera L, Gutierrez M, Ceron F, Garcia L. Evaluation of an episomal expression construct containing the cDNA of iduronate sulfatase in (IDS) in fibroblasts from a patient with hunter syndrome. J Inherit Metab Dis. 2002;25(Suppl.1):160. 32. Zolotukhin S. Production of recombinant adeno-associated virus vectors. Hum Gene Ther. 2005; 16: 551-7. 33. Zolotukhin S, Byrne B, Mason E, Zolotukhin I, Potter M, Chesnut K, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999;6:973-85. 34. Aucoin MG, Perrier M, Kamen AA. Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnol Adv. 2008;26:73-88. 35. Okoyama H, Chen C. Calcium phosphate mediated gene transfer into established cell lines. En: Murray EJ, editor. Methods in molecular biology: Gene transfer and expression protocols. Clifton: The Humana Press; 1991. p. 15-20. 36. Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy-a review. Stem Cells Dev. 2004;13:133-45. 37. Ward P, Clément N, Linden M. cis effects in adeno-associated virus type 2 replication. J Virol. 2007;81: 9976-89. 38. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998;72:1438-45. 39. Wu Z, Asokan A, Samulski R. Adeno-associated virus srotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14:316-27. 40. Toietta G, Severini G, Traversari C, Tomatsu S, Sukegawa K, Fukuda S, et al. Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro. Hum Gene Ther. 2001;12:2007-16. 41. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-6. 42. Lewinski MK, Bushman FD. Retroviral DNA integration-mechanism and consequences. Adv Genet. 2005;55:147-81. 43. Landgrebe J, Dierks T, Schamidt B, Figura Kv. The human SUMF1 gene, required for posttranslational sulfatase modification, defines a new gene family which is conserved from pro- to eukaryotes. Gene. 2003;316:47-56. 44. Cosma M, Pepe P, Annunziata I, Newbold R, Grompe M, Parenti G, et al. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003;113:445-56.; https://revistabiomedica.org/index.php/biomedica/article/view/85

  12. 12
    Academic Journal

    المصدر: Biomedica; Vol. 28 No. 4 (2008); 510-522 ; Biomédica; Vol. 28 Núm. 4 (2008); 510-522 ; 2590-7379 ; 0120-4157

    وصف الملف: application/pdf

    Relation: https://revistabiomedica.org/index.php/biomedica/article/view/56/57; https://revistabiomedica.org/index.php/biomedica/article/view/56/385; Shuh M, Beilke M. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/ lymphoma (ATLL) and tropical spastic paraparesis/ HTLV-associated myelopathy (TSP/HAM). Microsc Res Tech. 2005;68:176-96. 2. Vernant JC, Maurs L, Gessain A, Barin F, Gout O, Delaporte JM, et al. Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. Ann Neurol. 1987;21:123-30. 3. Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, et al. Chronic progressive myelophathy associated with elevated antibodies to human Tlymphotropic virus type I and adult T-cell leukemia like cells. Ann Neurol. 1987;21:117-22. 4. Zaninovic V, Galindo J, Blank A. Paraparesia espástica tropical en Colombia. En: Enfermedades asociadas con el virus HTLV-I. Cali: Fundación MAR; 1992. p. 77-86. 5. Bartholomew C, Jack N, Edwards J, Charles W, Corbin D, Cleghorn FR, et al. HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLVI- associated myelopathy/tropical spastic paraparesis. J Hum Virol. 1998;1:302-5. 6. Chávez M, Domínguez MC, Blank A, Quintana M, Eizuru Y, García-Vallejo F. Reconstrucción de la evolución molecular de la infección actual por el virus linfotrópico humano tipo I en Colombia. Biomédica. 2004;24:65-72. 7. Balcázar N, Sánchez G, García-Vallejo F. Sequence and phylogenetic analysis of Human T-Lymphotropic Virus type 1 from Tumaco, Colombia. Mem Inst Oswaldo Cruz. 2003 98:641-8 8. Trujillo JM, Concha M, Muñoz A, Bergonzoli G, Mora C, Borrero I, et al. Seroprevalence and cofactors of HTLV-I infection in Tumaco, Colombia. AIDS Res Hum Retroviruses. 1992;8:651-7. 9. Nakamura H, Kawakami A, Tominaga M, Hida A, Yamasaki S, Migita K, et al. Relationship between Sjögren’s syndrome and human T-lymphotropic virus type I infection: follow-up study of 83 patients. J Lab Clin Med. 2000;135:139-44. 10. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12:391-8. 11. Beger E, Deocharan E, Edelman M, Erblich B, Gu Y, Putterman C. A peptide DNA surrogate accelerates autoimmune manifestations and nephritis in lupus-prone mice. J Immunol. 2002;168:3617-26. 12. Bangham CR. HTLV-1 infections. J Clin Pathol. 2000;53:581-6. 13. Asquith B, Zhang Y, Mosley AJ, de Lara CM, Wallace DL, Worth A, et al. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc Natl Acad Sci USA. 2007; 104:8035-40. 14. Verdonck K, González E, van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7:266-81. 15. Trujillo JR, Mclane MF, Lee TH, Essex M. Molecular mimicry between the human immunodeficiency virus type 1 gp120 V3 loop and human brain proteins. J Virol. 1993;67:7711-5. 16. Levin MC, Krikavsky M, Berck J, Foley S, Rosenfeld M, Dalmau J, et al. Neuronal molecular mimicry in immune-mediated neurologic disease. Ann Neurol. 1998;44:87-98. 17. Levin MC, Lee SM, Kalume F, Morcos Y, Dohan FC Jr, Hasty KA, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med. 2002;8:509-13. 18. García-Vallejo F, Domínguez MC, Tamayo O. Autoimmunity and molecular mimicry in tropical spastic paraparesis/human T-lymphotropic virus-associated myelopathy. Braz J Med Biol Res. 2005;38:241-50. 19. Tanaka Y, Zeng L, Shiraki H, Shida H, Tozawa H. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization. J Immunol. 1991;147:354-60. 20. Lee B, Tanaka Y, Tozawa H. Monoclonal antibody defining tax protein of human T-cell leukemia virus type- I. Tohoku J Exp Med.1989;157:1-11. 21. Burnette WN. “Western blotting”: Electroforetic transfer of proteins from sodium dodecyl sulfate-polyacrilamide gels to unmodified nitrocellulose and radiographic detection with antibody and radiodinated protein. Anal Biochem. 1981;112:195-203. 22. Barin F, M’Boup S, Denis F, Kanki P, Allan JS, Lee TH, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet. 1985;2:1387-9. 23. Hsu S, Raine L, Fanger H. Use of avidine-biotineperoxidase complex (ABC) in immnuperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedure. J. Histochem Cytochem. 1981;29:577. 24. Shi SR, Iman A, Young L, Cote R, Taylor CR. Antigen retrieval immunohistochemistry under the influenza of using monoclonal antibodies. J Histochem Cytochem. 1995; 43:193-201. 25. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, et al. Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-Iassociated myelopathy/tropical spastic paraparesis and hyper-IgEaemic myelitis. J Neuroimmunol. 2001; 119: 297-305. 26. Wu X, Osoegawa M, Yamasaki K, Kawano Y, Ochi H, Horiuchi I, et al. Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV- 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci. 2000;177:24-31. 27. Horiuchi I, Kawano Y, Yamasaki K, Minohara M, Furue M, Taniwaki T, et al. Th1 dominance in HAM/ TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis. J Neurol Sci. 2000;172:17-24. 28. Azran I, Schavinsky-Khrapunsky Y, Aboud M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology. 2004;1:20-43 29. Barmak K, Harhaj E, Grant C, Alefantis T, Wigdahl B. Human T cell leukemia virus type I-induced disease: pathways to cancer and neurodegeneration. Virology. 2003;308:1-12. 30. Levin MC, Lee SM, Morcos Y, Brady J, Stuart J. Cross-reactivity between immunodominant human T lymphotropic virus type I tax and neurons: implications for molecular mimicry. J Infect Dis. 2002;186:1514-7 31. Lee SM, Dunnavant FD, Jang H, Zunt J, Levin MC. Autoantibodies that recognize functional domains of hnRNPA1 implicate molecular mimicry in the pathogenesis of neurological disease. Neurosci Lett. 2006;401:188-93. 32. Caporali R, Bugatti S, Bruschi E, Cavagna L, Montecucco C. Autoantibodies to heterogeneous nuclear ribonucleoproteins. Autoimmunity. 2005; 38: 25-32. 33. Princler GL, Julias JG, Hughes SH, Derse D. Roles of viral and cellular proteins in the expression of alternatively spliced HTLV-1 pX mRNAs. Virology. 2003;317:136-45. 34. Kress E, Hachem BH, Bex F, Gazzolo L, Duc M. Critical role of hnRNP A1 in HTLV-1 replication in human transformed T lymphocytes. Retrovirology. 2005;2:1-8.; https://revistabiomedica.org/index.php/biomedica/article/view/56

  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
    Academic Journal
  18. 18
  19. 19
  20. 20
    Academic Journal